Hauptman-Woodward Medical Research Institute, Inc., 700 Ellicot St., Buffalo, NY 14203, USA.
School of Science, RMIT University, Bundoora, VIC 3083, Australia.
Molecules. 2022 Oct 25;27(21):7206. doi: 10.3390/molecules27217206.
Human transthyretin (hTTR) can form amyloid deposits that accumulate in nerves and organs, disrupting cellular function. Molecules such as tafamidis that bind to and stabilize the TTR tetramer can reduce such amyloid formation. Here, we studied the interaction of VCP-6 (2-((3,5-dichlorophenyl)amino)benzoic acid) with hTTR. VCP-6 binds to hTTR with 5 times the affinity of the cognate ligand, thyroxine (T). The structure of the hTTR:VCP-6 complex was determined by X-ray crystallography at 1.52 Å resolution. VCP-6 binds deeper in the binding channel than T with the 3',5'-dichlorophenyl ring binding in the 'forward' mode towards the channel centre. The dichlorophenyl ring lies along the 2-fold axis coincident with the channel centre, while the 2-carboxylatephenylamine ring of VCP-6 is symmetrically displaced from the 2-fold axis, allowing the 2-carboxylate group to form a tight intermolecular hydrogen bond with Nζ of Lys15 and an intramolecular hydrogen bond with the amine of VCP-6, stabilizing its conformation and explaining the greater affinity of VCP-6 compared to T. This arrangement maintains optimal halogen bonding interactions in the binding sites, via chlorine atoms rather than iodine of the thyroid hormone, thereby explaining why the dichloro substitution pattern is a stronger binder than either the diiodo or dibromo analogues.
人转甲状腺素蛋白 (hTTR) 可以形成淀粉样沉积物,这些沉积物在神经和器官中积累,破坏细胞功能。像他达拉非这样与 TTR 四聚体结合并稳定其结构的分子可以减少这种淀粉样形成。在这里,我们研究了 VCP-6(2-((3,5-二氯苯基)氨基)苯甲酸)与 hTTR 的相互作用。VCP-6 与 hTTR 的结合亲和力是其天然配体甲状腺素 (T) 的 5 倍。通过 X 射线晶体学以 1.52 Å 的分辨率确定了 hTTR:VCP-6 复合物的结构。VCP-6 比 T 更深地结合在结合通道中,3',5'-二氯苯基环以朝向通道中心的“向前”模式结合。二氯苯基环沿 2 重轴与通道中心一致,而 VCP-6 的 2-羧基苯基胺环从 2 重轴对称位移,允许 2-羧基基团与 Lys15 的 Nζ形成紧密的分子间氢键,并与 VCP-6 的胺形成分子内氢键,稳定其构象并解释 VCP-6 比 T 具有更高的亲和力。这种排列方式通过氯原子而不是甲状腺激素的碘原子,在结合部位保持最佳的卤键相互作用,从而解释了为什么二氯取代模式比二碘或二溴类似物更强的结合剂。